Your browser doesn't support javascript.
loading
Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'.
de Franchis, Roberto; Bosch, Jaume; Garcia-Tsao, Guadalupe; Reiberger, Thomas; Ripoll, Cristina.
Afiliação
  • de Franchis R; Department of Biomedical and Clinical Sciences, University of Milan, Italy. Electronic address: roberto.defranchis@unimi.it.
  • Bosch J; Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland; Instituts d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and CIBERehd, University of Barcelona, Spain.
  • Garcia-Tsao G; Yale University, New Haven, USA; VA-CT Healthcare System, West Haven, USA.
  • Reiberger T; Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Ripoll C; Internal Medicine IV, Universitätsklinikum Jena, Friedrich Schiller University, Jena, Germany.
J Hepatol ; 77(2): 567-568, 2022 08.
Article em En | MEDLINE | ID: mdl-35526788
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Hipertensão Portal / Neoplasias Hepáticas Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: J Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Hipertensão Portal / Neoplasias Hepáticas Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: J Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2022 Tipo de documento: Article